Exposure to Treatment and Incidence of Treatment-Related Adverse Events During Collection Phase
| . | SCF + Filgrastim . | Filgrastim . |
|---|---|---|
| No. of patients | 55 | 47 |
| Median duration of cytokine exposure (d) | 12 | 13 |
| Range | 2-26 | 9-29 |
| Cumulative SCF dose (μg/kg) | 239.2 | — |
| Range | 39.3-520.0 | — |
| Cumulative filgrastim dose (μg/kg) | 59.8 | 65.2 |
| Range | 15.7-131.4 | 45.0-143.4 |
| No. (%) with treatment-related adverse event | 44 (80%) | 8 (17%) |
| Application site | 24 (44%) | 0 (0%) |
| Injection site erythema | 12 (22%) | 0 (0%) |
| Injection site reaction | 8 (15%) | 0 (0%) |
| Skin and appendages | 14 (25%) | 1 (2%) |
| Rash | 7 (13%) | 0 (0%) |
| Erythema | 3 (5%) | 1 (2%) |
| Fever | 6 (11%) | 1 (2%) |
| Metabolic/nutrition | 7 (13%) | 0 (0%) |
| LDH increased | 7 (13%) | 0 (0%) |
| Musculo-skeletal | 7 (13%) | 5 (11%) |
| Pain skeletal | 4 (7%) | 1 (2%) |
| Pain back | 3 (5%) | 2 (4%) |
| Myalgia | 0 (0%) | 2 (4%) |
| . | SCF + Filgrastim . | Filgrastim . |
|---|---|---|
| No. of patients | 55 | 47 |
| Median duration of cytokine exposure (d) | 12 | 13 |
| Range | 2-26 | 9-29 |
| Cumulative SCF dose (μg/kg) | 239.2 | — |
| Range | 39.3-520.0 | — |
| Cumulative filgrastim dose (μg/kg) | 59.8 | 65.2 |
| Range | 15.7-131.4 | 45.0-143.4 |
| No. (%) with treatment-related adverse event | 44 (80%) | 8 (17%) |
| Application site | 24 (44%) | 0 (0%) |
| Injection site erythema | 12 (22%) | 0 (0%) |
| Injection site reaction | 8 (15%) | 0 (0%) |
| Skin and appendages | 14 (25%) | 1 (2%) |
| Rash | 7 (13%) | 0 (0%) |
| Erythema | 3 (5%) | 1 (2%) |
| Fever | 6 (11%) | 1 (2%) |
| Metabolic/nutrition | 7 (13%) | 0 (0%) |
| LDH increased | 7 (13%) | 0 (0%) |
| Musculo-skeletal | 7 (13%) | 5 (11%) |
| Pain skeletal | 4 (7%) | 1 (2%) |
| Pain back | 3 (5%) | 2 (4%) |
| Myalgia | 0 (0%) | 2 (4%) |